✦ LIBER ✦

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Scribed by Walter H Gotlieb; Frederic Amant; Suresh Advani; Chanchal Goswami; Hal Hirte; Diane Provencher; Naresh Somani; S Diane Yamada; Jean-Francois Tamby; Ignace Vergote

Book ID: 117785858
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 196 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70338-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of aflibercept in patie

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

✍ Nicoletta Colombo; Giorgia Mangili; Serafina Mammoliti; Mårten Kalling; Bengt Th 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 260 KB

Intravenous aflibercept in patients with

Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study

✍ Tew, William P.; Colombo, Nicoletta; Ray-Coquard, Isabelle; del Campo, Josep M.; 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB

Randomised, placebo-controlled, double-b

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

✍ Rougier, Philippe; Riess, Hanno; Manges, Robert; Karasek, Petr; Humblet, Yves; B 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 916 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

✍ Karlan, B. Y.; Oza, A. M.; Richardson, G. E.; Provencher, D. M.; Hansen, V. L.; 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 190 KB

A double-blind, randomised, placebo-cont

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

✍ Gradishar, William J.; Kaklamani, Virginia; Sahoo, Tarini P.; Lokanatha, Dasappa 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 820 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB